表紙
市場調查報告書

Blau症候群全球市場:行業趨勢和預測(到2027年)

Global Blau Syndrome Market - Industry Trends and Forecast to 2027

出版商 Data Bridge Market Research Private Limited 商品編碼 953376
出版日期 內容資訊 英文 438 Pages
商品交期: 最快1-2個工作天內
價格
Blau症候群全球市場:行業趨勢和預測(到2027年) Global Blau Syndrome Market - Industry Trends and Forecast to 2027
出版日期: 2020年07月01日內容資訊: 英文 438 Pages
簡介

預計到2020年至2027年,全球Blau症候群市場規模將以11.9%的複合年增長率增長。

該報告分析了Blau症候群的全球診斷和治療市場,並概述了該病,市場的基本結構,促進和抑制該病的因素,市場規模的整體前景以及類型和治療領域。正在研究按管理路線,最終用戶,分銷渠道,區域,市場競爭環境,主要公司的概況等得出的詳細趨勢。

目錄

第1章簡介

第2章細分市場

第3章執行摘要

第4章世界Blau症候群市場:監管狀況

第5章市場概述

  • 市場促進因素
    • 增加生物療法的普及率
    • 用於治療與Blau症候群相關的症狀的藥物的出現
    • 對特定疾病的治療劑的需求很高
    • 醫療行業的進展
    • 標籤外藥品的供應情況
  • 市場約束因素
    • 無效和不真實的有效治療
    • 某些發展中國家的診斷率低
    • 現有藥物的許多副作用
  • 市場機會
    • 增加可支配收入
    • 擴展製藥公司的戰略發展
    • 新興市場
    • 加強研發
  • 挑戰
    • 缺少批准的藥物
    • 症候群的診斷成本高
    • 缺乏進行基因檢測的熟練資源

第6章COVID-19感染的傳播對全球Blau症候群的影響

  • 價格影響
  • 按需投放
  • 對供應鏈的影響
  • 製造商的戰略決策
  • 結論

第7章世界Blau症候群的類型

  • 概述
  • 治療
    • 皮質類固醇
    • 免疫抑製劑
    • TNF-A抑製劑
    • 眼藥水
    • 白介素受體
    • 其他
  • 診斷
    • 篩選
    • 確認檢查

第8章按治療領域分列的全球Blau症候群市場

  • 概述
  • 皮疹
  • 炎症
    • 粒細胞性皮炎
    • 滑膜炎
    • 葡萄膜炎
    • 肉芽腫性關節炎
    • 慢性關節炎
    • 其他

第9章按管理途徑劃分的全球Blau症候群市場市場

  • 概述
  • 口服藥
    • 錠劑
    • 膠囊
    • 其他
  • 非口服
    • 靜脈給藥
    • 皮下給藥
    • 其他
  • 局部
    • 藥膏
    • 溶液
    • 其他
  • 其他

第10章最終用戶的世界Blau症候群市場

  • 概述
  • 醫院
  • 診斷中心
  • 診所
  • 家庭醫療
  • 其他

第11章全球Blau症候群市場市場(按分銷渠道)

  • 概述
  • 醫院藥房
  • 零售藥房
  • 在線藥房
  • 直接出價
  • 其他

第12章按地區分列的世界Blau症候群市場

  • 概述
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 荷蘭
    • 西班牙
    • 俄羅斯
    • 瑞士
    • 土耳其
    • 奧地利
    • 挪威
    • 匈牙利
    • 立陶宛
    • 愛爾蘭
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 澳大利亞
    • 韓國
    • 印度
    • 新加坡
    • 馬來西亞
    • 泰國
    • 印度尼西亞
    • 菲律賓
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 秘魯
    • 南美洲
  • 中東/非洲
    • 沙特阿拉伯
    • 南非
    • 阿拉伯聯合酋長國
    • 以色列
    • 科威特
    • 埃及
    • 其他中東和非洲國家

第13章世界Blau症候群市場與公司狀況

  • 公司佔有率分析:全球市場
  • 公司佔有率分析:北美市場
  • 公司佔有率分析:歐洲市場
  • 公司佔有率分析:亞太市場

第14章SWOT分析

第15章公司簡介

  • NOVARTIS AG
  • AMGEN INC.
  • PFIZER INC.
  • JANSSEN PHARMACEUTICALS, INC (JOHNSON & JOHNSON SERVICES, INC.的子公司)
  • ABBVIE INC.
  • ACCORD HEALTHCARE
  • ALKEM LABS
  • AMNEAL PHARMACEUTICALS LLC
  • CENTOGENE N.V.
  • F. HOFFMANN-LA ROCHE LTD
  • FULGENT GENETICS
  • HIKMA PHARMACEUTICALS PLC
  • INVITAE CORPORATION
  • MYLAN N.V.
  • ONCODESIGN
  • SALIX PHARMACEUTICALS (BAUSCH HEALTH COMPANIES INC.的子公司)
  • SWEDISH ORPHAN BIOVITRUM AB (PUBL)
  • TEVA PHARMACEUTICAL USA INC. (TEVA PHARMACEUTICAL INDUSTRIES LTD.的子公司)
  • ZYDUS PHARMACEUTICALS, INC. (ZYDUS CADILAソ子會社)

第16章問卷調查

第17章相關分析

目錄

Global Blau syndrome market is projected to register a healthy CAGR of 11.9% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Global Blau Syndrome Market, By Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey and Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and Rest of Middle East and Africa) - Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of global Blau syndrome market are:

  • Emergence of drugs used to treat symptoms associated with Blau syndrome
  • Advancement in health care industry

Market Players:

The key market players for global Blau syndrome market are listed below:

  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)
  • Mylan N.V.
  • Hikma Pharmaceuticals PLC
  • Teva Pharmaceutical U.S.A Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
  • Fulgent Genetics Inc.
  • Invitae Corporation
  • Swedish Orphan Biovitrum AB
  • Alkem Labs
  • Accord Healthcare
  • F. Hoffmann-La Roche Ltd
  • Zydus Pharmaceuticals (USA) Inc. (a subsidiary of Zydus cadila)
  • Amneal Pharmaceuticals LLC
  • Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.)
  • Centogene AG
  • Oncodesign

TABLE OF CONTENTS

1 INTRODUCTION 58

  • 1.1 OBJECTIVES OF THE STUDY 58
  • 1.2 MARKET DEFINITION 58
  • 1.3 OVERVIEW OF GLOBAL BLAU SYNDROME MARKET 58
  • 1.4 LIMITATIONS 60
  • 1.5 MARKETS COVERED 60

2 MARKET SEGMENTATION 64

  • 2.1 MARKETS COVERED 64
  • 2.2 GEOGRAPHICAL SCOPE 65
  • 2.3 YEARS CONSIDERED FOR THE STUDY 66
  • 2.4 CURRENCY AND PRICING 66
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 67
  • 2.6 MULTIVARIATE MODELLING 70
  • 2.7 THERAPEUTIC AREAS OF BLAU SYNDROME LIFELINE CURVE 70
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 71
  • 2.9 DBMR MARKET POSITION GRID 72
  • 2.10 VENDOR SHARE ANALYSIS 73
  • 2.11 SECONDARY SOURCES 74
  • 2.12 ASSUMPTIONS 74

3 EXECUTIVE SUMMARY 75

4 GLOBAL BLAU SYNDROME MARKET: REGULATIONS 80

5 MARKET OVERVIEW 82

  • 5.1 DRIVERS 84
    • 5.1.1 HIGH ADOPTION OF BIOLOGICAL THERAPIES 84
    • 5.1.2 EMERGENCE OF DRUGS USED TO TREAT SYMPTOMS ASSOCIATED WITH BLAU SYNDROME 84
    • 5.1.3 HIGH DEMAND OF DISEASE SPECIFIC TREATMENT 85
    • 5.1.4 ADVANCEMENTS IN HEALTH CARE INDUSTRY 85
    • 5.1.5 AVAILABILITY OF OFF LABEL DRUGS 86
  • 5.2 RESTRAINTS 87
    • 5.2.1 UNAVAILABILITY AND UNAFFORDABILITY OF EFFECTIVE TREATMENT 87
    • 5.2.2 POOR DIAGNOSIS RATE IN SOME DEVELOPING COUNTRIES 87
    • 5.2.3 LARGE NUMBER OF SIDE EFFECTS OF AVAILABLE DRUGS 87
  • 5.3 OPPORTUNITIES 88
    • 5.3.1 RISING DISPOSABLE INCOME 88
    • 5.3.2 RISING STRATEGIC INITIATIVES BY PHARMACEUTICAL COMPANIES 88
    • 5.3.3 EMERGING MARKETS 89
    • 5.3.4 INCREASING RESEARCH AND DEVELOPMENT 89
  • 5.4 CHALLENGES 90
    • 5.4.1 LACK OF APPROVED DRUGS 90
    • 5.4.2 HIGH COST ASSOCIATED WITH SYNDROME DIAGONSIS 90
    • 5.4.3 LACK OF SKILLED RESOURCE FOR PERFORMING GENETIC TESTS 90

6 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL BLAU SYNDROME MARKET 91

  • 6.1 PRICE IMPACT 91
  • 6.2 IMPACT ON DEMAND 91
  • 6.3 IMPACT ON SUPPLY CHAIN 92
  • 6.4 STRATEGIC DECISIONS FOR MANUFACTURERS 92
  • 6.5 CONCLUSION 93

7 GLOBAL BLAU SYNDROME MARKET, BY TYPE 94

  • 7.1 OVERVIEW 95
  • 7.2 TREATMENT 98
    • 7.2.1 CORTICOSTEROIDS 99
      • 7.2.1.1 PREDNISOLONE 99
      • 7.2.1.2 COMBINATION CORTICOSTEROIDS 99
      • 7.2.1.3 NAPROXEN 99
      • 7.2.1.4 OTHERS 99
    • 7.2.2 IMMUNOSUPPRESSANTS 99
      • 7.2.2.1 METHOTREXATE 100
      • 7.2.2.2 MYCOPHENOLATE MOFETIL 100
      • 7.2.2.3 AZATHIOPRINE 100
      • 7.2.2.4 OTHERS 100
    • 7.2.3 TNF-A INHIBITORS 100
      • 7.2.3.1 INFLIXIMAB 101
      • 7.2.3.2 ADALIMUMAB 101
      • 7.2.3.3 ETANERCEPT 101
      • 7.2.3.4 OTHERS 101
    • 7.2.4 OPTHALMIC MEDICATION 101
      • 7.2.4.1 PREDNISOLONE ACETATE 101
      • 7.2.4.2 TROPICAMIDE 101
      • 7.2.4.3 OTHERS 101
    • 7.2.5 INTERLEUKIN RECEPTOR 102
      • 7.2.5.1 ANAKINRA 102
      • 7.2.5.2 CANAKINUMAB 102
      • 7.2.5.3 OTHERS 102
    • 7.2.6 OTHERS 102
  • 7.3 DIAGNOSIS 102
    • 7.3.1 SCREENING 103
      • 7.3.1.1 LAB TEST 104
        • 7.3.1.1.1 BLOOD TEST 104
        • 7.3.1.1.2 SALIVA TEST 104
        • 7.3.1.1.3 OTHERS 104
      • 7.3.1.2 IMAGING TEST 104
        • 7.3.1.2.1 CT SCANS 104
        • 7.3.1.2.2 ULTRASOUNDS 105
        • 7.3.1.2.3 OTHERS 105
    • 7.3.2 CONFIRMATORY TEST 105
      • 7.3.2.1 SKIN BIOPSY 105
      • 7.3.2.2 GENETIC TEST 105
      • 7.3.2.3 OTHERS 105

8 GLOBAL BLAU SYNDROME MARKET, BY THERAPEUTIC AREAS 106

  • 8.1 OVERVIEW 107
  • 8.2 SKIN RASH 110
  • 8.3 INFLAMMATION 110
    • 8.3.1 GRANULOMATOUS DERMATITIS 112
    • 8.3.2 SYNOVITIS 112
    • 8.3.3 UVEITIS 112
    • 8.3.4 GRANULOMATOUS ARTHRITIS 112
    • 8.3.5 CHRONIC ARTHRITIS 112
    • 8.3.6 OTHERS 112

9 GLOBAL BLAU SYNDROME MARKET, BY ROUTE OF ADMINISTRATION 113

  • 9.1 OVERVIEW 114
  • 9.2 ORAL 117
    • 9.2.1 TABLET 118
    • 9.2.2 CAPSULE 118
    • 9.2.3 OTHERS 118
  • 9.3 PARENTERAL 118
    • 9.3.1 INTRAVENOUS 119
    • 9.3.2 SUBCUTANEOUS 119
    • 9.3.3 OTHERS 119
  • 9.4 TOPICAL 119
    • 9.4.1 OINTMENT 120
    • 9.4.2 SOLUTION 120
    • 9.4.3 OTHERS 120
  • 9.5 OTHERS 120

10 GLOBAL BLAU SYNDROME MARKET, BY END USER 122

  • 10.1 OVERVIEW 123
  • 10.2 HOSPITALS 125
  • 10.3 DIAGNOSTICS CENTERS 126
  • 10.4 CLINICS 127
  • 10.5 HOME HEALTHCARE 127
  • 10.6 OTHERS 128

11 GLOBAL BLAU SYNDROME MARKET, BY DISTRIBUTION CHANNEL 129

  • 11.1 OVERVIEW 130
  • 11.2 HOSPITAL PHARMACY 132
  • 11.3 RETAIL PHARMACY 133
  • 11.4 ONLINE PHARMACY 134
  • 11.5 DIRECT TENDER 135
  • 11.6 OTHERS 136

12 GLOBAL BLAU SYNDROME MARKET, BY GEOGRAPHY 137

  • 12.1 OVERVIEW 138
  • 12.2 NORTH AMERICA 143
    • 12.2.1 U.S. 152
    • 12.2.2 CANADA 157
    • 12.2.3 MEXICO 162
  • 12.3 EUROPE 167
    • 12.3.1 GERMANY 176
    • 12.3.2 FRANCE 181
    • 12.3.3 U.K. 186
    • 12.3.4 ITALY 191
    • 12.3.5 NETHERLANDS 196
    • 12.3.6 SPAIN 202
    • 12.3.7 RUSSIA 207
    • 12.3.8 SWITZERLAND 212
    • 12.3.9 TURKEY 218
    • 12.3.10 AUSTRIA 223
    • 12.3.11 NORWAY 228
    • 12.3.12 HUNGARY 233
    • 12.3.13 LITHUANIA 238
    • 12.3.14 IRELAND 243
    • 12.3.15 POLAND 248
    • 12.3.16 REST OF EUROPE 253
  • 12.4 ASIA PACIFIC 254
    • 12.4.1 JAPAN 263
    • 12.4.2 CHINA 268
    • 12.4.3 AUSTRAILA 273
    • 12.4.4 SOUTH KOREA 279
    • 12.4.5 INDIA 285
    • 12.4.6 SINGAPORE 290
    • 12.4.7 MALAYSIA 296
    • 12.4.8 THAILAND 301
    • 12.4.9 INDONESIA 306
    • 12.4.10 PHILIPPINES 312
    • 12.4.11 VIETNAM 318
    • 12.4.12 REST OF ASIA-PACIFIC 323
  • 12.5 SOUTH AMERICA 324
    • 12.5.1 BRAZIL 333
    • 12.5.2 ARGENTINA 338
    • 12.5.3 PERU 344
    • 12.5.4 REST OF SOUTH AMERICA 349
  • 12.6 MIDDLE EAST & AFRICA 350
    • 12.6.1 SAUDI ARABIA 359
    • 12.6.2 SOUTH AFRICA 365
    • 12.6.3 UAE 371
    • 12.6.4 ISRAEL 376
    • 12.6.5 KUWAIT 381
    • 12.6.6 EGYPT 386
    • 12.6.7 REST OF MIDDLE EAST & AFRICA 391

13 GLOBAL BLAU SYNDROME MARKET, COMPANY LANDSCAPE 392

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL 392
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 393
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE 394
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 395

14 SWOT 396

15 COMPANY PROFILES 397

  • 15.1 NOVARTIS AG 397
    • 15.1.1 COMPANY SNAPSHOT 397
    • 15.1.2 REVENUE ANALYSIS 397
    • 15.1.3 COMPANY SHARE ANALYSIS 398
    • 15.1.4 PRODUCT PORTFOLIO 398
    • 15.1.5 RECENT DEVELOPMENTS 398
  • 15.2 AMGEN INC. 399
    • 15.2.1 COMPANY SNAPSHOT 399
    • 15.2.2 REVENUE ANALYSIS 399
    • 15.2.3 COMPANY SHARE ANALYSIS 400
    • 15.2.4 PRODUCT PORTFOLIO 400
    • 15.2.5 RECENT DEVELOPMENTS 400
  • 15.3 PFIZER INC. 401
    • 15.3.1 COMPANY SNAPSHOT 401
    • 15.3.2 REVENUE ANALYSIS 401
    • 15.3.3 COMPANY SHARE ANALYSIS 402
    • 15.3.4 PRODUCT PORTFOLIO 402
    • 15.3.5 RECENT DEVELOPMENTS 402
  • 15.4 JANSSEN PHARMACEUTICALS, INC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 403
    • 15.4.1 COMPANY SNAPSHOT 403
    • 15.4.2 REVENUE ANALYSIS 403
    • 15.4.3 COMPANY SHARE ANALYIS 404
    • 15.4.4 PRODUCT PORTFOLIO 404
    • 15.4.5 RECENT DEVELOPMENT 404
  • 15.5 ABBVIE INC. 405
    • 15.5.1 COMPANY SNAPSHOT 405
    • 15.5.2 REVENUE ANALYSIS 405
    • 15.5.3 COMPANY SHARE ANALYSIS 406
    • 15.5.4 PRODUCT PORTFOLIO 406
    • 15.5.5 RECENT DEVELOPMENTS 406
  • 15.6 ACCORD HEALTHCARE 408
    • 15.6.1 COMPANY SNAPSHOT 408
    • 15.6.2 PRODUCT PORTFOLIO 408
    • 15.6.3 RECENT DEVELOPMENTS 408
  • 15.7 ALKEM LABS 409
    • 15.7.1 COMPANY SNAPSHOT 409
    • 15.7.2 REVENUE ANALYSIS 409
    • 15.7.3 PRODUCT PORTFOLIO 410
    • 15.7.4 RECENT DEVELOPMENT 410
  • 15.8 AMNEAL PHARMACEUTICALS LLC 411
    • 15.8.1 COMPANY SNAPSHOT 411
    • 15.8.2 REVENUE ANALYSIS 411
    • 15.8.3 PRODUCT PORTFOLIO 411
    • 15.8.4 RECENT DEVELOPMENTS 412
  • 15.9 CENTOGENE N.V. 413
    • 15.9.1 COMPANY SNAPSHOT 413
    • 15.9.2 REVENUE ANALYSIS 413
    • 15.9.3 PRODUCT PORTFOLIO 413
    • 15.9.4 RECENT DEVELOPMENTS 414
  • 15.10 F. HOFFMANN-LA ROCHE LTD 415
    • 15.10.1 COMPANY SNAPSHOT 415
    • 15.10.2 REVENUE ANALYSIS 415
    • 15.10.3 PRODUCT PORTFOLIO 416
    • 15.10.4 RECENT DEVELOPMENT 416
  • 15.11 FULGENT GENETICS 417
    • 15.11.1 COMPANY SNAPSHOT 417
    • 15.11.2 REVENUE ANALYSIS 417
    • 15.11.3 PRODUCT PORTFOLIO 417
    • 15.11.4 RECENT DEVELOPMENT 418
  • 15.12 HIKMA PHARMACEUTICALS PLC 419
    • 15.12.1 COMPANY SNAPSHOT 419
    • 15.12.2 REVENUE ANALYSIS 419
    • 15.12.3 PRODUCT PORTFOLIO 420
    • 15.12.4 RECENT DEVELOPMENTS 420
  • 15.13 INVITAE CORPORATION 421
    • 15.13.1 COMPANY SNAPSHOT 421
    • 15.13.2 REVENUE ANALYSIS 421
    • 15.13.3 PRODUCT PORTFOLIO 422
    • 15.13.4 RECENT DEVELOPMENTS 422
  • 15.14 MYLAN N.V. 423
    • 15.14.1 COMPANY SNAPSHOT 423
    • 15.14.2 REVENUE ANALYSIS 423
    • 15.14.3 PRODUCT PORTFOLIO 424
    • 15.14.4 RECENT DEVELOPMENTS 424
  • 15.15 ONCODESIGN 425
    • 15.15.1 COMPANY SNAPSHOT 425
    • 15.15.2 REVENUE ANALYSIS 425
    • 15.15.3 PRODUCT PORTFOLIO 425
    • 15.15.4 RECENT DEVELOPMENT 426
  • 15.16 SALIX PHARMACEUTICALS (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.) 427
    • 15.16.1 COMPANY SNAPSHOT 427
    • 15.16.2 REVENUE ANALYSIS 427
    • 15.16.3 PRODUCT PORTFOLIO 428
    • 15.16.4 RECENT DEVELOPMENT 428
  • 15.17 SWEDISH ORPHAN BIOVITRUM AB (PUBL) 429
    • 15.17.1 COMPANY SNAPSHOT 429
    • 15.17.2 REVENUE ANALYSIS 429
    • 15.17.3 PRODUCT PORTFOLIO 429
    • 15.17.4 RECENT DEVELOPMENTS 430
  • 15.18 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 431
    • 15.18.1 COMPANY SNAPSHOT 431
    • 15.18.2 REVENUE ANALYSIS 431
    • 15.18.3 PRODUCT PORTFOLIO 432
    • 15.18.4 RECENT DEVELOPMENTS 432
  • 15.19 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA) 433
    • 15.19.1 COMPANY SNAPSHOT 433
    • 15.19.2 REVENUE ANALYSIS 433
    • 15.19.3 PRODUCT PORTFOLIO 433
    • 15.19.4 RECENT DEVELOPMENTS 434

16 QUESTIONNAIRE 435

17 RELATED REPORTS 438

LIST OF FIGURES

  • FIGURE 1 GLOBAL BLAU SYNDROME MARKET: SEGMENTATION 64
  • FIGURE 2 GLOBAL BLAU SYNDROME MARKET : DATA TRIANGULATION 67
  • FIGURE 3 GLOBAL BLAU SYNDROME MARKET: DROC ANALYSIS 68
  • FIGURE 4 GLOBAL BLAU SYNDROME MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 69
  • FIGURE 5 GLOBAL BLAU SYNDROME MARKET: COMPANY RESEARCH ANALYSIS 69
  • FIGURE 6 GLOBAL BLAU SYNDROME MARKET: MULTIVARIATE MODELLING 70
  • FIGURE 7 GLOBAL BLAU SYNDROME MARKET: INTERVIEW DEMOGRAPHICS 71
  • FIGURE 8 GLOBAL BLAU SYNDROME MARKET: DBMR MARKET POSITION GRID 72
  • FIGURE 9 GLOBAL BLAU SYNDROME MARKET: VENDOR SHARE ANALYSIS 73
  • FIGURE 10 GLOBAL BLAU SYNDROME MARKET: SEGMENTATION 76
  • FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 77
  • FIGURE 12 HIGH ADOPTION OF BIOLOGICAL THERAPIES AND HIGH DEMAND OF DISEASE SPECIFIC TREATMENT IS DRIVING THE GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 78
  • FIGURE 13 TREATMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BLAU SYNDROME MARKET IN 2020 & 2027 78
  • FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET IN GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 79
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF GLOBAL BLAU SYNDROME MARKET 83
  • FIGURE 16 GLOBAL BLAU SYNDROME MARKET: BY TYPE, 2019 95
  • FIGURE 17 GLOBAL BLAU SYNDROME MARKET: BY TYPE, 2019-2027 (USD THOUSAND) 96
  • FIGURE 18 GLOBAL BLAU SYNDROME MARKET: BY TYPE, CAGR (2020-2027) 96
  • FIGURE 19 GLOBAL BLAU SYNDROME MARKET: BY TYPE, LIFELINE CURVE 97
  • FIGURE 20 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019 107
  • FIGURE 21 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND) 108
  • FIGURE 22 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027) 108
  • FIGURE 23 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE 109
  • FIGURE 24 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019 114
  • FIGURE 25 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD THOUSAND) 115
  • FIGURE 26 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027) 115
  • FIGURE 27 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 116
  • FIGURE 28 GLOBAL BLAU SYNDROME MARKET: BY END USER, 2019 123
  • FIGURE 29 GLOBAL BLAU SYNDROME MARKET: BY END USER, 2019-2027 (USD THOUSAND) 124
  • FIGURE 30 GLOBAL BLAU SYNDROME MARKET: BY END USER, CAGR (2020-2027) 124
  • FIGURE 31 GLOBAL BLAU SYNDROME MARKET: BY END USER, LIFELINE CURVE 125
  • FIGURE 32 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019 130
  • FIGURE 33 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND) 131
  • FIGURE 34 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 131
  • FIGURE 35 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 132
  • FIGURE 36 GLOBAL BLAU SYNDROME MARKET: SNAPSHOT (2019) 139
  • FIGURE 37 GLOBAL BLAU SYNDROME MARKET: BY REGION (2019) 140
  • FIGURE 38 GLOBAL BLAU SYNDROME MARKET: BY REGION (2020 & 2027) 140
  • FIGURE 39 GLOBAL BLAU SYNDROME MARKET: BY REGION (2019 & 2027) 141
  • FIGURE 40 GLOBAL BLAU SYNDROME MARKET: BY TYPE (2020-2027) 141
  • FIGURE 41 NORTH AMERICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 143
  • FIGURE 42 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 144
  • FIGURE 43 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 144
  • FIGURE 44 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 145
  • FIGURE 45 NORTH AMERICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 145
  • FIGURE 46 EUROPE BLAU SYNDROME MARKET: SNAPSHOT (2019) 167
  • FIGURE 47 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019) 168
  • FIGURE 48 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 168
  • FIGURE 49 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 169
  • FIGURE 50 EUROPE BLAU SYNDROME MARKET: BY TYPE (2020-2027) 169
  • FIGURE 51 ASIA PACIFIC BLAU SYNDROME MARKET: SNAPSHOT (2019) 254
  • FIGURE 52 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2019) 255
  • FIGURE 53 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 255
  • FIGURE 54 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 256
  • FIGURE 55 ASIA PACIFIC BLAU SYNDROME MARKET: BY TYPE (2020-2027) 256
  • FIGURE 56 SOUTH AMERICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 324
  • FIGURE 57 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 325
  • FIGURE 58 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 325
  • FIGURE 59 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 326
  • FIGURE 60 SOUTH AMERICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 326
  • FIGURE 61 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 350
  • FIGURE 62 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 351
  • FIGURE 63 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 351
  • FIGURE 64 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 352
  • FIGURE 65 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 352
  • FIGURE 66 GLOBAL BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 392
  • FIGURE 67 NORTH AMERICA BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 393
  • FIGURE 68 EUROPE BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 394
  • FIGURE 69 ASIA-PACIFIC BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 395